Evotec, Halozyme

Evotec gains on Halozyme's takeover pro­pos­al
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The news caused Evotec's shares to rise 18% in Europe while Halozyme's stock dropped 4.
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German biotech for €11.00 per share in cash, or about €2bn.
Germany’s Evotec Gets Takeover Interest From Halozyme
Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German drug developer at €2 billion ($2.1 billion). Most Read from BloombergUnder Trump,
Evotec jumps on report Halozyme expressed takeover interest
ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently expressed interest in purchasing Evotec for ~€11 per share, according to a Bloomberg report on Thursday,
Halozyme Therapeutics Bids to Acquire German Competitor Evotec
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.)
Evotec attracts takeover interest from Halozyme, Bloomberg says
EST Evotec (EVO) attracts takeover interest from Halozyme (HALO), Bloomberg says Published first on TheFly – the ultimate source
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
Evotec jumps as Halozyme confirms takeover interest (updated)
Evotec stock surges 10% as Halozyme Therapeutics expresses takeover interest, sparking investor excitement and speculation in the market.
FierceBiotech9h
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
MarketWatch6h
Evotec Shares Surge on $2.11 Billion Buyout Offer
Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...
Warburg Research Sticks to Their Buy Rating for Evotec (0IRF)
Warburg Research analyst Christian Ehmann maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of ...
FierceBiotech4d
Evotec, after stock-tanking blows, attracts private equity buyout interest: report
Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall ...
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...
RBC Capital Keeps Their Buy Rating on Evotec (0IRF)
RBC Capital analyst Charles Weston maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €11.60. The ...